Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marvin Swartz

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Schizophrenia Research|February 22, 2011
The association between weight change and symptom reduction in the CATIE schizophrenia trialEric Hermes, Henry Nasrallah, Vicki Davis, et al.
Community Mental Health Journal|November 30, 2010
Criminal justice system involvement among people with schizophreniaGreg Greenberg, Robert A Rosenheck, Steven K Erickson, et al.
Psychiatric Services (Washington, D.C.)|January 8, 2005
Use of leverage to improve adherence to psychiatric treatment in the communityJohn Monahan, Allison D Redlich, Jeffrey Swanson, et al.
The Journal of Behavioral Health Services & Research|February 5, 2008
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophreniaSandra G Resnick, Robert A Rosenheck, Jose M Canive, et al.
Psychiatric Services (Washington, D.C.)|August 10, 2005
Cost-sharing requirements and access to mental health care among medicare enrollees with schizophreniaEric P Slade, David S Salkever, Robert Rosenheck, et al.
PLOS Mental Health|September 2, 2025
Impact of insurance type on outpatient mental health treatment of US adultsLydia A Chwastiak, Scott Graupensperger, Heather Ringeisen, et al.
The American Journal of Psychiatry|December 8, 2006
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophreniaRobert A Rosenheck, Douglas L Leslie, Jody Sindelar, et al.
Psychiatric Services (Washington, D.C.)|September 23, 2024
Characterizing Schizophrenia Spectrum Disorders: Results of the U.S. Mental and Substance Use Disorders Prevalence StudyNatalie Bareis, Mark Edlund, Heather Ringeisen, et al.
Psychiatric Services (Washington, D.C.)|May 21, 2025
Prevalence of Past-Year Mental and Substance Use Disorders, 2021-2022Heather Ringeisen, Mark Edlund, Heidi Guyer, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 28, 2006
Baseline neurocognitive deficits in the CATIE schizophrenia trialRichard S E Keefe, Robert M Bilder, Philip D Harvey, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Schizophrenia Research|February 22, 2011
The association between weight change and symptom reduction in the CATIE schizophrenia trialEric Hermes, Henry Nasrallah, Vicki Davis, et al.
Community Mental Health Journal|November 30, 2010
Criminal justice system involvement among people with schizophreniaGreg Greenberg, Robert A Rosenheck, Steven K Erickson, et al.
Psychiatric Services (Washington, D.C.)|January 8, 2005
Use of leverage to improve adherence to psychiatric treatment in the communityJohn Monahan, Allison D Redlich, Jeffrey Swanson, et al.
The Journal of Behavioral Health Services & Research|February 5, 2008
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophreniaSandra G Resnick, Robert A Rosenheck, Jose M Canive, et al.
Psychiatric Services (Washington, D.C.)|August 10, 2005
Cost-sharing requirements and access to mental health care among medicare enrollees with schizophreniaEric P Slade, David S Salkever, Robert Rosenheck, et al.
PLOS Mental Health|September 2, 2025
Impact of insurance type on outpatient mental health treatment of US adultsLydia A Chwastiak, Scott Graupensperger, Heather Ringeisen, et al.
The American Journal of Psychiatry|December 8, 2006
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophreniaRobert A Rosenheck, Douglas L Leslie, Jody Sindelar, et al.
Psychiatric Services (Washington, D.C.)|September 23, 2024
Characterizing Schizophrenia Spectrum Disorders: Results of the U.S. Mental and Substance Use Disorders Prevalence StudyNatalie Bareis, Mark Edlund, Heather Ringeisen, et al.
Psychiatric Services (Washington, D.C.)|May 21, 2025
Prevalence of Past-Year Mental and Substance Use Disorders, 2021-2022Heather Ringeisen, Mark Edlund, Heidi Guyer, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 28, 2006
Baseline neurocognitive deficits in the CATIE schizophrenia trialRichard S E Keefe, Robert M Bilder, Philip D Harvey, et al.
Pageof 5